



May 30, 2026

To, Listing Department, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Ref: BSE Scrip Code: 544497	To, The National Stock Exchange of India Ltd. The Listing Department Exchange Plaza, Bandra – Kurla Complex, Mumbai – 400051, NSE Scrip Code: AHCL
--	---

Sub: Intimation for Press release of Audited Financial Results (Standalone and Consolidated) for the Quarter & Year Ended March 31, 2026.

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the Regulation) we hereby submit the Press release of Audited Financial Results (Standalone and Consolidated) for the Quarter & Year Ended March 31, 2026.

You are requested to take the above information on your record.

Thanking You.

Yours Faithfully,
For ANLON HEALTHCARE LIMITED

**PUNITKUMAR RASADIA
MANAGING DIRECTOR
DIN: 06696258**

Encl: As above

ANLON HEALTHCARE LIMITED

CIN No.: U24230GJ2013PLC077543

REGISTERED OFFICE: 101/102, Silver Coin Complex, Opp. Crystal Mall, Kalawad Road, Rajkot-360005, Gujarat (INDIA)

PHONE NO.: +91-7069690081/82 | Email: info@anlonhealthcare.com | www.anlon.in



ANLON HEALTHCARE REPORTS 43% REVENUE GROWTH, 48% EBITDA GROWTH AND 42% PAT GROWTH IN FY26; STRENGTHENS LONG-TERM GROWTH PLATFORM THROUGH STRATEGIC ACQUISITIONS

Rajkot, 29th May 2026 – Anlon Healthcare Limited, one of India’s leading manufacturers of high-purity pharmaceutical intermediates and active pharmaceutical ingredients (APIs), announced its **Audited Financial Results (Standalone and Consolidated) for Q4 and FY26**, reporting strong growth in revenue, profitability, and margins, supported by robust R&D execution and strategic capacity expansion initiatives.

Key Financial Highlights:

CONSOLIDATED FIGURES:

Particulars (₹ Cr)	FY25	FY26	Y-o-Y Change
Total Income	120.46	172.22	↑ 42.98%
EBITDA	32.38	47.77	↑ 47.55%
PAT	20.52	29.09	↑ 41.77 %

STANDALONE FIGURES:

Particulars (₹ Cr)	FY25	FY26	Y-o-Y Change
Total Income	120.46	176.26	↑ 46.32%
EBITDA	32.38	46.39	↑ 43.27%
PAT	20.52	27.81	↑ 35.53%

Key Developments During the Quarter

- Completed acquisition of **Bizotic Lifescience**, which is **now a subsidiary of Anlon Healthcare**, strengthening the Company’s manufacturing platform and growth capabilities.
- **Apiqo Organics** continues to strengthen backward integration capabilities and supply-chain efficiency across pharmaceutical intermediates and specialty chemical products.
- Continued development of **3 molecules for 2 global innovator companies under the CDMO business vertical**.
- Continued focus on expanding presence across pharmaceutical, nutraceutical, veterinary and personal care

Management Commentary:

Mr. Punitkumar Rasadia – Chairman & Managing Director of Anlon Healthcare Limited, commented on the company's strong results,

“FY26 has been a significant year in Anlon Healthcare’s growth journey as we delivered strong financial performance alongside meaningful strategic progress. **The Company reported consolidated Total Income of ₹172.22 Crores, registering a growth of 42.98% over FY25. EBITDA increased by 47.55% to ₹47.77 Crores, while Profit After Tax grew by 41.77% to ₹29.09 Crores.** The growth was driven by expanding demand across our pharmaceutical intermediates and API portfolio, improving operational efficiencies, and disciplined execution across key business verticals.

During the year, we strengthened our manufacturing and integration capabilities through the acquisitions of Apiqo Organics and Bizotic Lifescience, which now form an important part of our long-term growth platform. We also continued to advance our regulatory and innovation capabilities with 21 DMF filings and ongoing CDMO projects for global innovator companies. These initiatives position us well to capitalize on growing opportunities across APIs and pharmaceutical intermediates.

The global pharmaceutical industry continues to benefit from increasing outsourcing, supply-chain diversification, and rising demand for compliant manufacturing partners, while India remains a key beneficiary of the global China+1 strategy and policy support for domestic API manufacturing. Alongside our core pharmaceutical business, **we have also successfully diversified into the Industrial & Fine Chemicals segment**, which is witnessing encouraging traction and complements our existing manufacturing capabilities, customer relationships, and growth strategy.

Looking ahead, we remain focused on expanding our **product portfolio, strengthening regulated-market presence, scaling our CDMO business, and further growing our Industrial & Fine Chemicals vertical.** Supported by our expanded manufacturing platform, regulatory capabilities, diversified product portfolio, and strategic acquisitions, we remain confident of delivering **approximately 30% revenue CAGR over the next three years while working towards maintaining EBITDA margins in the range of 25–30%.”**

About Anlon Healthcare Limited

Incorporated in 2013 and headquartered in Rajkot, Gujarat, *Anlon Healthcare Limited* is a research-driven manufacturer of high-purity advanced pharmaceutical intermediates and APIs that serve as essential building blocks for finished dosage formulations.

The company is among the few Indian manufacturers of **Loxoprofen Sodium Dihydrate**, **Ketoprofen**, and **Dexketoprofen Trometamol** — key APIs used for pain and inflammation management. Its products cater to multiple sectors, including **pharmaceuticals, nutraceuticals, personal care, and animal health**.

With **400 MTPA installed capacity**, **four R&D centers** and a **global presence across 15+ countries**, Anlon continues to advance health through innovation, quality, and sustainability.

Disclaimer

This document contains forward-looking statements, which are not historical facts and are subject to risks and uncertainties such as government actions, local developments, and technological risks. The Company is not responsible for any actions taken based on these statements and does not commit to publicly updating them to reflect future events or circumstances.

For Further Information Please Contact

	ConfideLeap Partners info@confideleap.com +(91) 85911 45959 www.confideleap.com
---	--